Flavivirus fusion inhibitors

Details Flavivirus fusion inhibitors Flavivirus fusion inhibitors

2003-11-07

2008-08-26

Chen, Stacy B (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S186100

Reexamination Certificate

active

07416733

ABSTRACT:
The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses.

REFERENCES:
patent: 4810492 (1989-03-01), Fujita et al.
patent: 5514539 (1996-05-01), Bukh et al.
patent: 5610009 (1997-03-01), Watanabe et al.
patent: 5747239 (1998-05-01), Wang et al.
patent: 6037348 (2000-03-01), Colacino et al.
patent: 6117640 (2000-09-01), Srivastava et al.
patent: 0 982 402 (2000-03-01), None
patent: WO 99/55366 (1999-11-01), None
patent: WO 00/09701 (2000-02-01), None
patent: WO 00/75337 (2000-12-01), None
patent: WO 01/51673 (2001-07-01), None
patent: WO 02/072835 (2002-09-01), None
patent: WO 02/081754 (2002-10-01), None
Robert F. Garry, et al., “Proteomics Computational Analysis Suggest that Hepatitis C Virus E1 and Pestivirus E2 Envelope Glycoproteins and Truncated Class II Fusion Proteins,”Virology, 307:255-265 (2003).
Hoffman-LaRoche and Trimeris, “Roche and Trimeris Announce 24-Week Results from Second Pivotal Study of HIV Inhibitor T-20”, trimeris.com
ews/pr/2002/020516.html. (2002).
Richard J. Kuhn et al., “Structure of Dengue Virus: Implications for Flavivirus Organization, Maturation, and Fusion”,Cell, 108:717-725 (2002).
R.J. Medinas et al., “C-Terminal gp40 Peptide Analogs Inhibit Feline Immunodeficiency Virus: Cell Fusion and Virus Spread”,Journal of Virology, 76(18)9079-9086 (2002).
Julien Lescar, et al., “The Fusion Glycoprotein Shell of Semliki Forest Virus: An Icosahedral Assembly Primed for Fusogenic Activation at Endosomal pH”,Cell, 105:137-148 (2001).
Tatiana Suárez, “Membrane Interface-Interacting Sequences within the Ectodomain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein: Putative Role During Viral Fusion”,Journal of Virology, 74(17):8038-8047 (2000).
M. Flint et al., “The Role of Hepatitis C Virus Glycoproteins in Infection”,Medical Virology, 10:101-117 (2000).
Mike Flint et al., “Functional Analysis of Cell Surface-Expressed Hepatitis C Virus E2 Glycoprotein”,Journal of Virology, 73(8):6782-6790 (1999).
Winfried Weissenhorn et al., “Crystal Structure of the Ebola Virus Membrane Fusion Subunit, GP2, from the Envelope Glycoprotein Ectodomain”,Molecular Cell, 2:605-616 (1998).
Carl Wild et al., “A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell-Cell Fusion”,Aids Research and Human Retroviruses, 9(11):1051-1053 (1993).
Carl Wild et al., “Peptides Corresponding to a Predictive α-Helical Domain of Human Immunodeficiency Virus Type 1 gp41 are Potent Inhibitors of Virus Infection”,Proc. Natl. Acad. Sci. USA, 91:9770-9774 (1994).
William R. Gallaher, “Detection of a Fusion Peptide Sequence in the Transmembrane Protein of Human Immunodeficiency Virus”,Cell, 50:327-328 (1987).
Volkova, T.D.; et al, “The Protein E 98-113 Sequence as the Fusion Site of Tick-Borne Encephalitis Virus with a Cellular Membrane”, Bioorganicheskaya Khimiya (1998), vol. 24, No. 9, p. 676-681. (Abstract Only).
Volkova, T.D., et al, “A Monoclonal Antibody That Recognizes The Predicted Tick-Borne Encephalitis Virus E Protein Fusion Sequence Blocks Fusion” Archives of Virology (1999), vol. 144, p. 1035-1039.
Allison, S.L., et al, “Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E”, Journal of Virology (2001), vol. 75, No. 9, p. 4268-4275.
Stiasny, K., et al, “Membrane Interactions of the Tick-Borne Encephalitis Virus Fusion Protein E at Low pH”, Journal of Virology (2002), vol. 76, No. 8, p. 3784-3790.
Crill, W.D., et al, “Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells”, Journal of Virology (2001), vol. 75, No. 16, p. 7769-7773.
Bhardwaj, S., et al, “Biophysical Characterization and Vector-Specific Antagonist Activity of Domain III of the Tick-Borne Flavivirus Envelope Protein”, Journal of Virology (2001), vol. 75, No. 8, p. 4002-4007.
Rey, F.A., et al, “The Envelope Glycoprotein From Tick-Borne Encephalitis Virus at 2 Å Resolution”, Nature (1995), vol. 375, p. 291-298.
Hung, S., et al, “Analysis of the Steps Involved in Dengue Virus Entry into Host Cells”, Virology (1999), vol. 257, p. 156-167.
Shai, Y.,Functional Domains within Fusion Proteins: Prospectives for Development of Peptide Inhibitors of Viral Cell Fusion, Bioscience Reports (2000), vol. 20, No. 6, p. 535-555.
Ryman KD et al. (1997) Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes,J. Gen. Virol.78:1353-1356.
http://srs.ebi.ac.uk/srsbin/cgi-bin/wgetz?-e+[uniprot-id:Q06526—9FLAV]|[uniprot-acc:Q06526—9FLAV]+-noSession Q06526—9 FLAV Jan. 11, 1996.

Affiliated with

Also associated with

Rating

Flavivirus fusion inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Flavivirus fusion inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Flavivirus fusion inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4012855